Sepsis caused by bacterial infection is an increasingly serious problem, responsible for hundreds of thousands of deaths every year. As current antibacterial drugs become increasingly powerless against evolving bacterial strains, such MRSA, new antibacterial drugs with a barrier to resistance are urgently needed.

Prosetta’s work on developing antiviral drugs allowed us to identify small molecules which modulate the assembly of multi-protein complexes within cells. While bacteria occupy a different branch of the tree of life than eukaryotes, the importance of assembly for maintaining homeostasis— and the potentially lethal consequences of aberrant assembly— led us to believe that bacteria must also carry out and rely on assembly. We screened assembly modulating compounds against bacteria and found multiple hits with antibacterial activity. The compound which we are currently advancing is active against both gram positive and gram negative bacteria, including resistant strains and growth from biofilms.

Prosetta is actively seeking academic and industry partnerships to advance our anti-bacterial program. If you are interested in collaborating or investing resources, please contact us at info@prosetta.com.